May 17, 2018 / 1:43 PM / 2 months ago

BRIEF-Biolinerx To Present Overall Survival Data At Eha From Phase 2A Study Of Bl-8040 In R/R Aml Patients

May 17 (Reuters) - BioLine RX Ltd:

* BIOLINERX TO PRESENT OVERALL SURVIVAL DATA AT EHA FROM PHASE 2A STUDY OF BL-8040 IN R/R AML PATIENTS

* BIOLINE RX LTD - BL-8040 IN COMBINATION WITH CYTARABINE SHOWED SIGNIFICANTLY IMPROVED OVERALL SURVIVAL COMPARED TO HISTORICAL DATA IN TRIAL Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below